One Pager as on July 31, 2025
![]() | Prudent portfolio of investments across companies and sectors. |
![]() | Actively managed by professional fund managers for potential long term capital appreciation. |
![]() | Opportunity to participate in successful businesses through equity market. |
Sector | MMMCF* | Nifty 500 Multicap 50:25:25 TRI |
Financial Services | 30.62% | 28.69% |
Healthcare | 14.57% | 8.50% |
Capital Goods | 8.80% | 8.16% |
Information Technology | 6.30% | 7.31% |
Automobile And Auto Components | 5.05% | 6.21% |
*Mahindra Manulife Multi Cap Fund
Data as on July 31, 2025
Security | % to Net Assets |
ICICI Bank Limited | 3.63% |
Divi's Laboratories Limited | 3.51% |
Glenmark Pharmaceuticals Limited | 3.48% |
Laurus Labs Limited | 3.42% |
HDFC Bank Limited | 3.14% |
Indus Towers Limited | 2.85% |
UltraTech Cement Limited | 2.67% |
Reliance Industries Limited | 2.49% |
PI Industries Limited | 2.06% |
Mphasis Limited | 1.92% |
Total | 29.17% |
Fresh Additions | Complete Exits |
Security | Security |
HDFC Asset Management Company Limited | Trent Limited |
IDFC First Bank Limited | BSE Limited |
Blue Star Limited | Axis Bank Limited |
Infosys Limited | National Aluminium Company |
Polycab India Limited | Mahindra Manulife Mutual Fund |
Neuland Laboratories Limited | Protean eGov Technologies Limited |
Fortis Healthcare Limited | Colgate Palmolive (India) Limited |
Sri Lotus Developers and Realty Ltd. | Oil India Limited |
Mankind Pharma Limited | - |
Syngene International Limited | - |
Note: The companies/stock(s) referred above are only for the purpose of disclosure of significant portfolio changes during the month and should not be construed as recommendation to buy/sell/ hold. The fund manager may or may not choose to hold these companies/stocks, from time to time. Investors are requested to consult their financial, tax and other advisors before taking any investment decision(s). Data as on July 31, 2025
Turnover Ratio (Last 1 year) | 1.04 |
Standard Deviation | 14.58% |
Beta | 0.94 |
Sharpe Ratio# | 1.26 |
Jenson's Alpha | 0.1491 |
#Risk-free rate assumed to be 5.54% (MIBOR as on 31-07-25) - Source: www.mmda.org
Note: As per AMFI guidelines for factsheet, the ratios are calculated based on month rolling returns
for last 3 years. Data as on July 31, 2025
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 11-May-17.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.
Since inception returns of the scheme is calculated on face value of Rs. 10 invested at inception. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Manish Lodha is managing this fund since December 21, 2020. Ms. Fatema Pacha is managing this scheme since October 16, 2020. *Based on standard investment of Rs. 10,000 made at the beginning of the relevant period.
^Benchmark ^^Additional Benchmark. CAGR – Compounded Annual Growth Rate. Inception/Allotment date: 11-May-17.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments.Returns greater than 1 year period are compounded annualized. For SIP returns, monthly investment of equal amounts invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).
^Benchmark CAGR – Compounded Annual Growth Rate.
Past performance may or may not be sustained in future and should not be used as a basis of comparison with other investments. The performance details provided above are of Growth Option under Regular Plan. Different Plans i.e Regular Plan and Direct Plan under the scheme has different expense structure. Mr. Manish Lodha manages 10 schemes and Ms. Fatema Pacha manages 8 schemes each of Mahindra Manulife Mutual Fund. The performance data for the schemes which have not completed one year has not been provided.
Performance as on July 31, 2025
This product is suitable for investors who are seeking*:
• Medium to Long term capital
appreciation.
• Investment predominantly in
equity and equity related securities
including derivatives.
*Investors should consult their financial advisers if in doubt about whether the product is suitable for them.